Traverse Biotech Announces A World-Wide License Agreement With Genmab To Develop And Commercialize A Novel Cancer Bispecific Antibody
Portfolio Pulse from Benzinga Newsdesk
Traverse Biotech has signed a license agreement with Genmab to develop and commercialize a bispecific antibody for cancer immunotherapy. The antibody was created using Genmab's proprietary DuoBody bispecific antibody technology platform. Traverse will use its operational and development expertise to advance and commercialize the bispecific antibody program.
September 12, 2023 | 1:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genmab has entered into a licensing agreement with Traverse Biotech for the development and commercialization of a bispecific antibody for cancer immunotherapy. This could potentially increase Genmab's revenues and market presence.
The licensing agreement with Traverse Biotech allows Genmab to leverage its proprietary DuoBody bispecific antibody technology platform. This could potentially lead to the development of a novel oncology product, which could increase Genmab's revenues and market presence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100